The Wake-Up Call Britain Needs to Hear
Here’s a number that should worry Downing Street: £200 million. That’s how much tax revenue the UK stands to lose just from AstraZeneca upgrading its New York listing. And that’s just the beginning.
Investment bank Peel Hunt is sounding the alarm: scrap stamp duty on share trades, or watch Britain’s biggest companies pack their bags for Wall Street. Why? Because the US doesn’t charge stamp duty on stock trades, and UK companies are starting to notice.
AstraZeneca’s making the first move, but if it works out, expect a domino effect that could gut the London Stock Exchange and wipe out £4.5 billion in annual stamp duty receipts.
Why AstraZeneca’s Move Changes Everything
AstraZeneca isn’t abandoning London just yet, but it’s testing the waters. The pharma giant is upgrading from depositary receipts to a direct NYSE listing—a move that’ll shift more trading volume to New York.
No stamp duty in the US means lower trading costs. Lower costs mean more investors. More US trading volume could eventually make London irrelevant for AstraZeneca shares.
And here’s the kicker: if this strategy pays off, AstraZeneca might ditch its London listing entirely. That alone would slash stamp duty receipts by 5%.
Charles Hall, head of research at Peel Hunt stated: “Boards would be negligent if they did not consider this.”
The Domino Effect That Could Gut the FTSE
Think AstraZeneca’s an isolated case? Think again.
If Britain’s largest company successfully shifts trading volume to New York, every other FTSE 100 board will be asking the same question: why are we paying stamp duty when we don’t have to?
The math is simple. Stamp duty adds 0.5% to every share purchase in the UK. For institutional investors moving billions, that’s real money. Wall Street offers the same access to capital without the tax bill.
Britain’s already struggling to compete with New York’s deeper liquidity and higher valuations. Adding a tax disadvantage into the mix? That’s not a competitive edge—it’s a self-inflicted wound.
The £4.5 Billion Question
Stamp duty on shares currently brings in roughly £4.5 billion annually. Lose that, and the Treasury has a problem.
But Peel Hunt argues scrapping stamp duty could actually be revenue-positive. How? Higher equity valuations mean more capital gains tax when investors eventually sell. Plus, you keep the companies—and all the economic activity they generate—in the UK.
Hall frames it as an existential choice: “Do we want to have one of the leading equity markets in the world, and retain our largest companies, or are we prepared to let the revenues leave?”
It’s not just about tax receipts. Lose the FTSE heavyweights and you lose jobs, prestige, and Britain’s status as a global financial hub.
What Happens Next?
The ball’s in the government’s court. Stick with stamp duty and risk a slow-motion exodus to New York. Scrap it and gamble that higher valuations offset the lost revenue.
AstraZeneca’s move has shifted this from a theoretical debate to an urgent policy question. Other countries don’t charge stamp duty on shares. Britain does. That competitive disadvantage is now impossible to ignore.
The Treasury needs to act fast. Once a few major companies make the jump, momentum becomes hard to reverse.
Key Takeaways
Britain’s stamp duty on shares is pushing FTSE 100 companies toward New York. AstraZeneca’s NYSE upgrade could cost £200 million in tax receipts and trigger broader departures. Peel Hunt recommends scrapping the tax entirely—arguing that higher equity valuations would offset lost revenue. The government faces a choice: reform or watch London’s status as a leading stock exchange slowly evaporate.
Want to stay sharp on UK finance policy? Keep an eye on how the Treasury responds—this could reshape Britain’s capital markets for decades.
FAQ: Stamp Duty and the FTSE Exodus
Q1: What is stamp duty on shares?
A: It’s a 0.5% tax charged on share purchases in the UK. Investors pay it when buying British stocks, but not when trading on US exchanges. This creates a cost disadvantage for London-listed companies.
Q2: Why is AstraZeneca upgrading its US listing?
A: To make it easier for American investors to trade its shares without paying UK stamp duty. This could shift trading volume from London to New York, reducing costs and potentially boosting liquidity.
Q3: How much revenue does stamp duty generate?
A: Around £4.5 billion annually. Losing major FTSE 100 companies to New York could significantly erode this figure.
Q4: Would scrapping stamp duty actually help the Treasury?
A: Peel Hunt argues yes—higher equity valuations from increased trading activity could generate more capital gains tax revenue. Plus, keeping major companies in London preserves broader economic benefits.
Q5: Could other FTSE 100 companies follow AstraZeneca?
A: Absolutely. If AstraZeneca’s strategy succeeds, other boards will face pressure to explore similar moves. No company wants to disadvantage its shareholders by paying avoidable taxes.
DISCLAIMER
Effective Date: 15th July 2025
The information provided on this website is for informational and educational purposes only and reflects the personal opinions of the author(s). It is not intended as financial, investment, tax, or legal advice.
We are not certified financial advisers. None of the content on this website constitutes a recommendation to buy, sell, or hold any financial product, asset, or service. You should not rely on any information provided here to make financial decisions.
We strongly recommend that you:
- Conduct your own research and due diligence
- Consult with a qualified financial adviser or professional before making any investment or financial decisions
While we strive to ensure that all information is accurate and up to date, we make no guarantees about the completeness, reliability, or suitability of any content on this site.
By using this website, you acknowledge and agree that we are not responsible for any financial loss, damage, or decisions made based on the content presented.
MORE NEWS
Disclosure & Editorial Standards
MJBurrows is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this website — including articles, calculators, and tools — is for general informational and educational purposes only. It does not constitute personal financial, investment, tax, or legal advice and does not take into account your individual circumstances, financial situation, or objectives.
Nothing on this site is a personal recommendation to buy, sell, hold, or otherwise deal in any financial product, asset, or service. You should always conduct your own research and seek advice from a qualified, FCA-regulated financial adviser before making any financial decisions.
Our calculators produce estimates based on simplified models using HMRC-published rates for the current tax year. They cannot account for every individual circumstance and should not be relied upon as exact figures. Tax rules and rates may change — verify current rates with HMRC or a qualified tax adviser.
Projections are not guarantees. Where our tools show future values (investment growth, pension projections, compound interest), these are hypothetical illustrations based on assumed growth rates. Past performance does not guarantee future results. The value of investments can go down as well as up.
Market data displayed on this site is provided by third-party sources including Twelve Data, Yahoo Finance, and CoinGecko. We do not guarantee the accuracy, completeness, or timeliness of third-party data.
This content is designed for UK residents and reflects UK tax rules, thresholds, and legislation. It may not apply to other jurisdictions.
Using this website does not create a professional-client relationship of any kind. MJBurrows is not responsible for any financial loss, damage, or decision made based on the content presented. By using this site, you accept these terms.
This disclaimer may be updated from time to time without prior notice. Last reviewed: 23 April 2026.
MJBurrows is an independent UK personal finance publication, written and edited by Matthew Burrows. There is no parent company, no investor group, and no advertising sales team — decisions about what to cover and how to frame it are made by Matthew alone. Our full Editorial Policy sets out how the site operates in detail.
Commercial model. As of April 2026, MJBurrows generates no revenue. The site carries no display advertising, no affiliate links, no sponsored content, no paid product placements, and no pay-for-coverage arrangements. If this changes in future, it will be disclosed openly on the Editorial Policy page.
Sources. Articles and tools reference primary sources — HM Revenue & Customs (HMRC), gov.uk, the Bank of England, the Office for National Statistics (ONS), the Financial Conduct Authority (FCA), Companies House, and UK government departmental publications (DWP, Treasury). Calculator data uses HMRC-published rates for the 2026/27 tax year. Market data (tickers, asset prices) is provided by Twelve Data, Yahoo Finance, and CoinGecko.
Verification. Every published article is fact-checked before going live. Numerical claims are traced to their primary source, quotes are checked against the original speaker or document, and calculator outputs are tested against HMRC worked examples. See our verification and accuracy policy for the full process.
Corrections. If you spot an error, please report it via the Corrections page. A three-tier severity system commits to specific response times:
- Tier 1 — Urgent (material reader harm, defamatory statements, regulatory or legal issues): acknowledged within 24 hours, page actioned within 24 hours, correction published within 48 hours of confirmation.
- Tier 2 — High (significant factual errors that misinform readers): acknowledged within 3 working days, correction published within 7 working days of confirmation.
- Tier 3 — Standard (minor factual errors, dated references, missing context): acknowledged within 7 working days, correction published at the next regular content review (within the quarter).
Significant corrections are logged on the public Corrections log.
Updates and review cadence. Calculators are reviewed at least quarterly, plus event-driven updates when HMRC publishes new rates (Budget, Autumn Statement, new tax year). Guides are reviewed at least twice a year, with major rewrites whenever underlying regulation changes. Tax-year-sensitive content is prioritised for review at the April tax-year transition.
Get in touch. For editorial enquiries — corrections, story tips, reader questions — the address is contact@mjburrows.com. The contact page is at mjburrows.com/contact. Every email is read personally by Matthew.
